Immunicom Presents Promising Preliminary Data from Multiple Studies in Late-Stage Cancer Patients at ISFA / E-ISFA Conference

SAN DIEGO–(BUSINESS WIRE)– #biotech–Immunicom, Inc., a clinical-stage biotechnology company pioneering “subtractive” advanced cancer therapies, presented promising preliminary data from trials investigating ImmunopheresisTM therapy for metastatic, refractory, solid tumor cancer patients who previously failed multiple lines of therapy. The results presented by Immunicom’s Chief Medical Officer, Dr. Robert Segal, at the 2021 ISFA/E-ISFA virtual joint conference established that Immunopheresis administere
Click here to view original post